Login to Your Account



ECC Roundup


Tuesday, October 1, 2013
• Exelixis Inc., of South San Francisco, provided updated results from BRIM7, an ongoing Phase Ib trial conducted by Roche AG and Genentech, Exelixis’ collaborator and part of Roche, of Basel, Switzerland, the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor cobimetinib (GDC-0973/XL518) in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription